$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000144702821000027 Filed on May 05, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$2.113M	$1.491M
YoY Change	41.72%	119.59%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.850M	$3.550M
YoY Change	8.45%	-19.5%
% of Gross Profit
Research & Development	$13.78M	$10.42M
YoY Change	32.32%	-29.2%
% of Gross Profit
Depreciation & Amortization	$443.0K	$500.0K
YoY Change	-11.4%	-1.77%
% of Gross Profit
Operating Expenses	$17.79M	$14.64M
YoY Change	21.53%	-26.35%
Operating Profit	-$15.68M	-$13.15M
YoY Change	19.24%	-31.51%
Interest Expense	$772.0K	$1.041M
YoY Change	-25.84%	8575.0%
% of Operating Profit
Other Income/Expense, Net	-$705.0K	-$714.0K
YoY Change	-1.26%	-82.39%
Pretax Income	-$16.38M	-$13.86M
YoY Change	18.18%	-40.39%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.38M	-$13.86M
YoY Change	18.18%	-40.39%
Net Earnings / Revenue	-775.25%	-929.64%
Basic Earnings Per Share	-$0.21	-$0.25
Diluted Earnings Per Share	-$0.21	-$0.25
COMMON SHARES
Basic Shares Outstanding	93.43M shares	67.68M shares
Diluted Shares Outstanding	93.43M shares	67.68M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$132.0M	$84.90M
YoY Change	55.43%	-23.24%
Cash & Equivalents	$79.42M	$26.42M
Short-Term Investments	$52.54M	$58.50M
Other Short-Term Assets	$4.100M	$2.400M
YoY Change	70.83%	242.86%
Inventory
Prepaid Expenses
Receivables	$1.265M	$1.072M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$137.3M	$88.33M
YoY Change	55.48%	-21.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.584M	$8.176M
YoY Change	-19.47%	-15.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$3.200M
YoY Change	-100.0%	-81.9%
Other Assets	$0.00	$233.0K
YoY Change	-100.0%
Total Long-Term Assets	$8.899M	$14.28M
YoY Change	-37.69%	-85.24%
TOTAL ASSETS
Total Short-Term Assets	$137.3M	$88.33M
Total Long-Term Assets	$8.899M	$14.28M
Total Assets	$146.2M	$102.6M
YoY Change	42.51%	-50.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$400.0K	$3.600M
YoY Change	-88.89%	56.52%
Accrued Expenses	$6.100M	$400.0K
YoY Change	1425.0%	-93.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.693M	$4.031M
YoY Change	66.04%	-54.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$25.40M	$25.30M
YoY Change	0.4%	289.23%
Total Long-Term Liabilities	$25.40M	$25.30M
YoY Change	0.4%	289.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.693M	$4.031M
Total Long-Term Liabilities	$25.40M	$25.30M
Total Liabilities	$32.09M	$29.36M
YoY Change	9.31%	4.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.066B	-$986.9M
YoY Change	7.97%	18.74%
Common Stock	$1.013B	$911.1M
YoY Change	11.2%	3.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$114.1M	$73.26M
YoY Change
Total Liabilities & Shareholders Equity	$146.2M	$102.6M
YoY Change	42.51%	-50.95%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$16.38M	-$13.86M
YoY Change	18.18%	-40.39%
Depreciation, Depletion And Amortization	$443.0K	$500.0K
YoY Change	-11.4%	-1.77%
Cash From Operating Activities	-$17.88M	-$15.45M
YoY Change	15.71%	-6.8%
INVESTING ACTIVITIES
Capital Expenditures	$99.00K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$18.32M	-$2.400M
YoY Change	-863.33%	-103.93%
Cash From Investing Activities	$18.22M	-$2.401M
YoY Change	-858.89%	-103.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$26.42M	$12.32M
YoY Change	114.53%	447.82%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$26.87M	$12.48M
YoY Change	115.32%	392.15%
NET CHANGE
Cash From Operating Activities	-$17.88M	-$15.45M
Cash From Investing Activities	$18.22M	-$2.401M
Cash From Financing Activities	$26.87M	$12.48M
Net Change In Cash	$27.17M	-$5.383M
YoY Change	-604.74%	-111.45%
FREE CASH FLOW
Cash From Operating Activities	-$17.88M	-$15.45M
Capital Expenditures	$99.00K	$0.00
Free Cash Flow	-$17.98M	-$15.45M
YoY Change	16.35%	-6.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	numberOfSegments
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-34949
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	ARBUTUS BIOPHARMA CORP
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0597776
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Veterans Circle
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Warminster
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	18974
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	469-0914
CY2021Q1	dei	City Area Code CityAreaCode	267
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2021Q1	dei	Security12b Title Security12bTitle	Common Shares, without par value
CY2021Q1	dei	Trading Symbol TradingSymbol	ABUS
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96387749	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79421000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52251000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	52540000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	71017000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1265000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1312000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4115000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3124000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	137341000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	127704000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8063000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7621000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6584000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6927000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2315000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2405000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	44000	USD
CY2021Q1	us-gaap	Assets Assets	146240000	USD
CY2020Q4	us-gaap	Assets Assets	137080000	USD
CY2021Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6063000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8901000	USD
CY2021Q1	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	198000	USD
CY2020Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	250000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	432000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	390000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6693000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9541000	USD
CY2021Q1	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19366000	USD
CY2020Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19554000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3555000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2477000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2593000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	32091000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	35114000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	35114000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	35114000	USD
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2021Q1	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	152620000	USD
CY2020Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	149408000	USD
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96245371	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96245371	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89678722	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89678722	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	1013118000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	985939000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62133000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60751000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1065554000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1045961000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48168000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48171000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	114149000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	101966000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	146240000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137080000	USD
CY2021Q1	us-gaap	Revenues Revenues	2113000	USD
CY2020Q1	us-gaap	Revenues Revenues	1491000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13370000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10416000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3847000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3553000	USD
CY2020Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	112000	USD
CY2021Q1	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2021Q1	us-gaap	Depreciation Depreciation	443000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	500000	USD
CY2021Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	129000	USD
CY2020Q1	us-gaap	Restructuring Charges RestructuringCharges	57000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	17789000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	14638000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15676000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13147000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	39000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	345000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	772000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	1041000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	28000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-18000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-705000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-714000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16381000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13861000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16381000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-13861000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	3212000	USD
CY2020Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2978000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19593000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16839000	USD
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93434378	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93434378	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67683586	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67683586	shares
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	3000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	251000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16378000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13610000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	101966000	USD
CY2021Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1647000	USD
CY2021Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	40000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26419000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	208000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	208000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	247000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16381000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16381000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	114149000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	114149000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	72744000	USD
CY2020Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1460000	USD
CY2020Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	180000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12315000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	166000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	252000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-13861000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	73256000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16381000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-13861000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	443000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1635000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1445000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-44000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-10000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	129000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	112000	USD
CY2021Q1	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	959000	USD
CY2020Q1	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	656000	USD
CY2021Q1	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	771000	USD
CY2020Q1	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	1039000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-159000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-47000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-132000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	857000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	439000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2796000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3602000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-116000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-131000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17881000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15453000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2030000	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	24369000	USD
CY2021Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	20350000	USD
CY2020Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	21968000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	99000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18221000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2401000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26419000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12315000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	208000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	166000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	247000	USD
CY2020Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26874000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12481000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-44000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27170000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5383000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52251000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31799000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	79421000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26416000	USD
CY2021Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	3212000	USD
CY2020Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2978000	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of business and future operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a clinical-stage, biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (“HBV”) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s two lead product candidates are AB-729, the Company’s proprietary subcutaneously-delivered RNA interference (“RNAi”) product candidate that suppresses HBsAg expression, and AB-836, the Company’s proprietary next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is currently in an ongoing Phase 1a/1b clinical trial and a Phase 2 clinical trial in collaboration with Assembly Biosciences, Inc. (“Assembly”). The Company initiated a Phase 1a/1b clinical trial for AB-836 in the first quarter of 2021 with initial data expected in the second half of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021, the Company had an aggregate of $132.0 million in cash, cash equivalents and investments in marketable securities. The Company believes that these cash resources will be sufficient to fund its operations through the third quarter of 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Impact </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus continues to spread globally, has been declared a pandemic by the World Health Organization and has spread to nearly every country in the world. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society. The pandemic has resulted in and will likely continue to result in significant disruptions to businesses. A number of countries and other jurisdictions around the world have implemented extreme measures to try and slow the spread of the virus. These measures include the closing of businesses and requiring people to stay in their homes, the latter of which raises uncertainty regarding the ability to travel to hospitals in order to participate in clinical trials. Additional measures that have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, include shortages and delays in the supply chain, as well as prohibitions in certain countries on enrolling subjects in new clinical trials. Future disruptions related to the COVID-19 pandemic could negatively impact the Company’s plans and timelines for the remainder of 2021 and beyond, including enrolling and monitoring subjects in its clinical trials.</span></div>
CY2021Q1	abus	Number Of Products NumberOfProducts	2	product
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	132000000.0	USD
CY2021Q1	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	1	subsidiary
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35000000.0	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30400000	shares
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3600000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	129000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3555000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2953000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	112000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3065000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	52523000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52540000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	71003000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	71017000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52500000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	71000000.0	USD
CY2021Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2020Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2021Q1	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2021Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	355000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2994000	USD
CY2021Q1	abus	Accrued Research And Development AccruedResearchAndDevelopment	4112000	USD
CY2020Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	1653000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	690000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	679000	USD
CY2021Q1	abus	Accrued Payroll Current AccruedPayrollCurrent	896000	USD
CY2020Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	3566000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9000	USD
CY2021Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6063000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8901000	USD
CY2020Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19554000	USD
CY2019Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	18992000	USD
CY2021Q1	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	959000	USD
CY2020Q1	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	656000	USD
CY2021Q1	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	771000	USD
CY2020Q1	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	1039000	USD
CY2021Q1	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19366000	USD
CY2020Q1	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19375000	USD
CY2021Q1	abus	Royalty Entitlements RoyaltyEntitlements	2	product
CY2021Q1	us-gaap	Revenues Revenues	2113000	USD
CY2020Q1	us-gaap	Revenues Revenues	1491000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.33
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.35
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1635000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1445000	USD

Files In Submission

Name	View Source	Status
0001447028-21-000027-index-headers.html	Edgar Link	pending
0001447028-21-000027-index.html	Edgar Link	pending
0001447028-21-000027.txt	Edgar Link	pending
0001447028-21-000027-xbrl.zip	Edgar Link	pending
a2021-q110xqex311.htm	Edgar Link	pending
a2021-q110xqex312.htm	Edgar Link	pending
a2021-q110xqex321.htm	Edgar Link	pending
a2021-q110xqex322.htm	Edgar Link	pending
abus-20210331.htm	Edgar Link	pending
abus-20210331.xsd	Edgar Link	pending
abus-20210331_cal.xml	Edgar Link	unprocessable
abus-20210331_def.xml	Edgar Link	unprocessable
abus-20210331_g1.jpg	Edgar Link	pending
abus-20210331_htm.xml	Edgar Link	completed
abus-20210331_lab.xml	Edgar Link	unprocessable
abus-20210331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2021 Q1 Form 10-Q Financial Statement

#000144702821000027 Filed on May 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2021 Q1 Form 10-Q Financial Statement

#000144702821000027 Filed on May 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus